[Current Standard of Care in Squamous Cell Carcinoma of the Head and Neck (SCCHN) - Prevention, diagnostics, prognostication and therapy].
The standard of care in squamous cell carcinoma of the head and neck (SCCHN) has recently undergone some major shifts in prevention, diagnostics, staging, prognostication and therapy.Prevention: Subtypes of the human papilloma virus (HPV) have been identified as causative agent for HPV-driven oropharyngeal carcinomas nearly two decades ago. Vaccination against HPV is now recommended for all girls and boys at the age of 9 to 14 years by the Standing Committee on Vaccination at the Robert Koch Institute (STIKO).Diagnostics: 18F-FDG PET/CT allows for a reduction of surgical procedures and is now reimbursed by the german health care system in certain indications. In N2/N3-disease after definitive chemoradiotherapy a FDG PET/CT is indicated to prevent neck dissection in PET negative patients. Moreover, a FDG PET CT is indicated in case of suspected recurrence of laryngeal carcinoma and as staging procedure in patients with cervical manifestation of CUP syndrome.Staging/prognostication: The favorable prognosis of HPV-driven oroparhyngeal carcinomas is now reflected by the 8th edition of the TNM classification. Therapeutic decisions should still be based on the established criteria of the 7th edition.Locally advanced disease: Treatment de-intensification strategies for HPV positive oropharyngeal carcinomas are currently evaluated. So far, the already published trials have reported a disadvantage for less intensive regimens. Therefore, de-intensification should not be practiced in current standard of care.Palliative systemic therapy: Checkpoint inhibitors nivolumab and pembrolizumab are the new standard of care after progression on platinum based therapies. In the Keynote-048 trial, treatment with either pembrolizumab alone (CPS > 1) or its combination with platin+ 5-flourouracil was superior to the current first line standard PFC.